open access
View PDF
Download PDF filePage views 94
Article views/downloads 62
Get Citation
E-mail alerts
Gynecological complications and treatment strategies in patients after hematopoietic stem cell transplantation
Kinga Wdowiarz1, Malgorzata Reinholz-Jaskolska1, Malgorzata Radowicka2, Miroslaw Wielgos3, Bronislawa Pietrzak4
'); var $authorName = $('
').appendTo($authorBox); $authorName.html($span.find(".author-name").html()); if ($span.find(".orcid-link").length) { var $orcid = $span.find(".orcid-link"); $orcid.clone().appendTo($authorBox).append($('' + $orcid.attr("data-orcid-id") + '')); } $span.find("sup").each(function() { var $affiliation = $(this); $('
' + $affiliation.attr("title").trim() + '
').appendTo($authorBox); }); new _v.tooltips.tooltip($a, $authorBox, {class: 'affiliationInBox', positionParams: {offsetTop: 10}}); return false; }); });
DOI: 10.5603/gpl.102573
Pubmed: 39812354
Abstract
In women after hematopoietic stem cell transplantation (HSCT), complications associated with the original disease and therapies used both before and after transplantation often occur, which significantly affects their quality of life. The most common gynaecological complications include secondary cancers, premature ovarian insufficiency (POI), infertility and chronic graft-versus-host disease (cGVHD). Cervical cancer is the most common secondary genital cancer in patients after HSCT. Regular screening and vaccination against HPV (Human Papillomavirus) can significantly reduce the risk for its occurrence. The specific complication after allogeneic hematopoietic stem cell transplantation is graft-versus-host disease (GVHD), the genital form of which can lead to labial and vaginal adhesions, significantly reducing the women’s quality of life. The basis of treatment is local steroid therapy and immunosuppression. A consequence of chemotherapy and radiation therapy may be damage to the gonads leading to premature ovarian insufficiency and the onset of menopause symptoms. The basis of treatment is systemic hormone therapy used until middle age when natural menopause is reached. Women after HSCT who are of reproductive age also suffer from infertility. An important role of the doctor is to educate patients about the risk for infertility and to suggest appropriate methods of preserving fertility before starting treatment. The recommended procedure for fertility preservation is cryopreservation of embryos or oocytes. The freezing and retransplantation of ovarian tissue is becoming an increasingly popular method of fertility protection.
Preventive examinations and early detection and treatment of gynaecological complications significantly improve the comfort of life and health of women after HSCT.
Keywords: hematopoietic stem cell transplantationgraft vs host diseaseprimary ovarian insufficiencyhormone replacement therapy
Article available in PDF format
View PDF
Download PDF fileReferences
- Machowicz R. Historia przeszczepiania szpiku w Polsce. Nowotwory J Oncol. 2014; 64(5): 460–465.
- Czerwiński J. "Poltransplant Biuletyn Informacyjny 2023".
- Frey Tirri B, Häusermann P, Bertz H, et al. Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. Bone Marrow Transplant. 2015; 50(1): 3–9.
- Liu HL, Chen YH, Chung CH, et al. Risk of secondary malignancies in hematopoietic stem cell transplantation recipients: a nationwide population-based study in Taiwan. Balkan Med J. 2023; 40(2): 131–138.
- Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009; 113(5): 1175–1183.
- Kolb HJ, Socié G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 1999; 131(10): 738–744.
- Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 19(2): 464–471.
- Gravitt PE. Evidence and impact of human papillomavirus latency. Open Virol J. 2012; 6: 198–203.
- Savani BN, Stratton P, Shenoy A, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008; 14(9): 1072–1075.
- Negri G, Herz M, Deola S, et al. Abnormal cervical cytology after allogeneic bone marrow transplantation. Am J Clin Pathol. 2014; 142(2): 222–226.
- Shanis D, Merideth M, Pulanic TK, et al. Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. Semin Hematol. 2012; 49(1): 83–93.
- Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127(23): 2824–2832.
- Petrosky E, Bocchini JA, Hariri S, et al. Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11): 300–304.
- Stratton P, Battiwalla M, Tian X, et al. Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. JAMA Oncol. 2020; 6(5): 1–10.
- Cordonnier C, Einarsdottir S, Cesaro S, et al. European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6): e200–e212.
- FDA NEWS RELEASE: FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old.
- https://www.fda.gov/news-events/fda-newsroom/press-announcements.
- -Bidziński M, Zimmer M, Czajkowski K, et al. Cervical cancer screening guidelines of the Polish Society of Gynecologists and Obstetricians — June 2022. Ginekol Perinatol Prakt. 2022; 7(2): 96–98.
- Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011; 117(17): 4651–4657.
- Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002; 100(2): 406–414.
- Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013; 4: 163.
- Anasetti C, Logan B, Lee S, et al. Peripheral-Blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367(16): 1487–1496.
- Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol. 2007; 110(5): 1041–1049.
- Hirsch P, Leclerc M, Rybojad M, et al. Female genital chronic graft-versus-host disease. Transplantation. 2012; 93(12): 1265–1269.
- Carpenter P, Kitko C, Elad S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biology of Blood and Marrow Transplantation. 2015; 21(7): 1167–1187.
- Bachmann GA, Rosen R, Pinn VW, et al. Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med. 2006; 51(6): 447–456.
- Cizek SM, El-Bietar J, Rubinstein J, et al. Pediatric and young adult vulvovaginal graft-versus-host disease. Biol Blood Marrow Transplant. 2019; 25(12): 2408–2415.
- Smith Knutsson E, Nicklasson M, Björk Y, et al. Late follow-up of genital and ophthalmologic chronic graft-vs-host disease in females after allogeneic stem cell transplantation. Acta Obstet Gynecol Scand. 2022; 101(3): 364–373.
- Zantomio D, Grigg AP, MacGregor L, et al. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant. 2006; 38(8): 567–572.
- Jagasia M, Greinix H, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015; 21(3): 389–401.e1.
- Spiryda LB, Laufer MR, Soiffer RJ, et al. Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003; 9(12): 760–765.
- Lara LA, De Andrade JM, Mauad LM, et al. Genital manifestation of graft-vs.-host disease: a series of case reports. J Sex Med. 2010; 7(9): 3216–3225.
- Smith Knutsson E, Björk Y, Broman AK, et al. Genital chronic graft-versus-host disease in females: a cross-sectional study. Biol Blood Marrow Transplant. 2014; 20(6): 806–811.
- Frey Tirri B, Häusermann P, Bertz H, et al. Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD. Bone Marrow Transplant. 2015; 50(1): 3–9.
- Dignan FL, Scarisbrick JJ, Cornish J, et al. Haemato-oncology Task Force of British Committee for Standards in Haematology, British Society for Blood and Marrow Transplantation. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012; 158(1): 62–78.
- Carter A, Robison LL, Francisco L, et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant. 2006; 37(11): 1023–1029.
- Jadoul P, Anckaert E, Dewandeleer A, et al. Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. Fertil Steril. 2011; 96(1): 126–133.e3.
- Salooja N, Szydlo RM, Socie G, et al. Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001; 358(9278): 271–276.
- Webber L, Davies M, Anderson R, et al. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016; 31(5): 926–937.
- Teinturier C, Hartmann O, Valteau-Couanet D, et al. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998; 22(10): 989–994.
- Schimmer AD, Quatermain M, Imrie K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998; 16(7): 2359–2363.
- Holm K, Nysom K, Brocks V, et al. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant. 1999; 23(3): 259–263.
- Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999; 106(12): 1265–1272.
- Su H, Li H, Zhang H, et al. Menopausal symptoms and quality of life in female survivors treated with hematopoietic stem cell transplantation. Front Psychiatry. 2023; 14: 1050959.
- Piccioni P, Scirpa P, D'Emilio I, et al. Hormonal replacement therapy after stem cell transplantation. Maturitas. 2004; 49(4): 327–333.
- Committee opinion no. 698: Hormone therapy in primary ovarian insufficiency. Obstet Gynecol. 2017; 129(5): e134–e141.
- ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013; 121(4): 887–890.
- Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005; 23(28): 6919–6930.
- Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol. 2003; 189(1): 81–88.
- Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996; 87(7): 3045–3052.
- Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(19): 1994–2001.
- Jach R, Spaczynski R, Kurzawa R, et al. Updating the recommendations of the working group for the preservation of fertility in oncological and hematological patients and other patients treating gonadier therapies "ONCOFERTILITY" (GROF) of the Polish Society of Oncological Gynecology regarding cryopreserves and autologous transplant. Ginekol Pol. 2021 [Epub ahead of print].
- Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertility and Sterility. 2019; 112(6): 1022–1033.
- Andersen CY, Bollerup AC, Kristensen SG. Defining quality assurance and quality control measures in connection with ovarian tissue cryopreservation and transplantation: a call to action. Hum Reprod. 2018; 33(7): 1201–1204.
') .append($($headInfo.html())) .insertBefore($('.articleTitle')) ; }); })();
This site uses cookies
We use cookies on our website. We use them to ensure the proper functioning of the site and, if you give us your consent, for purposes we set, such as analytics or marketing. We would like to ask your permission to store them on your device. We will not run optional cookies until you have enabled them yourself. If you would like to learn more about how cookies work and how we process personal data related to them, please visit our Privacy Policy page
About cookies
Necessary cookies
Allways active
These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.
Analytical cookies
As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.
Community cookies
These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.
Marketing cookies
These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.